ES2160124T3 - Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades. - Google Patents

Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.

Info

Publication number
ES2160124T3
ES2160124T3 ES94919263T ES94919263T ES2160124T3 ES 2160124 T3 ES2160124 T3 ES 2160124T3 ES 94919263 T ES94919263 T ES 94919263T ES 94919263 T ES94919263 T ES 94919263T ES 2160124 T3 ES2160124 T3 ES 2160124T3
Authority
ES
Spain
Prior art keywords
bcl
medicines
diseases
prevention
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919263T
Other languages
English (en)
Inventor
John C Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22070248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160124(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of ES2160124T3 publication Critical patent/ES2160124T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO DE TRATAMIENTO DE UNA ENFERMEDAD O CONDICION PATOLOGICA QUE DA COMO RESULTADO LA MUERTE CELULAR APOPTOTICA. EL METODO INCLUYE EL AUMENTO DE LA ACTIVIDAD DE BCL-2 EN CELULAS AFECTADAS POR LA ENFERMEDAD O CONDICION PATOLOGICA. LAS ENFERMEDADES O CONDICIONES PATOLOGICAS PUEDEN INCLUIR, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS, CANCER E INFECCIONES VIRALES. TAMBIEN SE PROPORCIONA UN METODO DE PROLONGACION DE LA SUPERVIVENCIA IN VIVO DE CELULAS TRASPLANTADAS PARA EL TRATAMIENTO DE UNA ENFERMEDAD O CONDICION PATOLOGICA. EL METODO INCLUYE EL INCREMENTO DE LA ACTIVIDAD DE BCL-2 EN UNA POBLACION DE CELULAS Y EL TRASPLANTE A UN SUJETO DE LA POBLACION DE CELULAS QUE TIENEN ACTIVIDAD BCL-2 INCREMENTADA. LAS ENFERMEDADES O CONDICIONES PATOLOGICAS PUEDEN INCLUIR, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS, CANCER E INFECCIONES VIRALES. SE PROPORCIONA UN METODO PARA MEJORAR LA SENSIBILIDAD DE CELULAS MALIGNAS PARA LA TERAPIA QUE INCLUYE LA REDUCCION DE LA ACTIVIDADDE BCL-2 EN LAS CELULAS MALIGNAS. TAMBIEN SE PROPORCIONAN MEDIANTE LA INVENCION AQUI DESCRITA, METODOS PARA IDENTIFICAR COMPUESTOS QUE ALTERAN LA MUERTE CELULAR APOPTOTICA Y PARA MEJORAR LA PRODUCCION DE ANTICUERPO MONOCLONAL.
ES94919263T 1993-05-26 1994-05-26 Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades. Expired - Lifetime ES2160124T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/066,556 US5550019A (en) 1993-05-26 1993-05-26 Methods of identifying compounds which alter apoptosis

Publications (1)

Publication Number Publication Date
ES2160124T3 true ES2160124T3 (es) 2001-11-01

Family

ID=22070248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919263T Expired - Lifetime ES2160124T3 (es) 1993-05-26 1994-05-26 Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.

Country Status (10)

Country Link
US (4) US5550019A (es)
EP (2) EP0751709B2 (es)
JP (2) JP3704348B2 (es)
AT (1) ATE204704T1 (es)
CA (1) CA2163439C (es)
DE (1) DE69428130T3 (es)
DK (1) DK0751709T3 (es)
ES (1) ES2160124T3 (es)
PT (1) PT751709E (es)
WO (1) WO1994027426A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5539085A (en) * 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US6231852B1 (en) 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2739561B1 (fr) * 1995-10-06 1997-12-26 Inst Nat Sante Rech Med Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
AUPN896596A0 (en) * 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
WO1998002579A1 (en) * 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof
CA2295500A1 (en) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Methods of controlling axonal growth
US6558900B2 (en) * 1996-07-12 2003-05-06 Emory University Regulation of apoptosis and in vitro model for studies thereof
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
CA2285709A1 (en) 1997-04-01 1998-10-08 The General Hospital Corporation Molecular marker for muscle stem cells
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
WO2000002578A1 (fr) * 1998-07-10 2000-01-20 Meiji Milk Products Co., Ltd. Remedes contre les maladies liees a l'apoptose
AU5789500A (en) * 1999-07-09 2001-01-30 Burnham Institute, The A method for determining the prognosis of cancer patients by measuring levels ofbag expression
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20010053769A1 (en) 2000-01-21 2001-12-20 Christiane Ferran Use of pro-apoptotic factors in treatment of atherosclerosis
US6773894B1 (en) * 2000-01-21 2004-08-10 Biochain Institute, Inc. Isolation and extraction of subcellularly compartmentalized protein
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7419825B2 (en) * 2001-04-20 2008-09-02 Children's Hospital Of Orange County Isolation of neural stem cells using gangliosides and other surface markers
DE10228187A1 (de) * 2002-06-24 2004-01-22 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Testsystem zum Nachweis von Krebserkrankungen
US8017323B2 (en) * 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
WO2005014017A1 (ja) * 2003-08-08 2005-02-17 Yuji Shino 癌治療用医薬組成物
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
PL2540820T3 (pl) * 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ITMI20060384A1 (it) * 2006-03-03 2007-09-04 Umberto Cornelli Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica
US20090069223A1 (en) * 2007-08-21 2009-03-12 Childs Ed W Method for treatment of vascular hyperpermeability
US20100189802A1 (en) * 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
US8192420B2 (en) 2007-12-20 2012-06-05 Acclarent, Inc. Iontophoresis methods
WO2009122580A1 (ja) * 2008-04-03 2009-10-08 株式会社ツムラ 抑肝散のバイオアッセイ方法
EP2271325A4 (en) 2008-04-11 2011-11-09 Cytotech Labs Llc METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS
US20110059191A1 (en) * 2008-05-23 2011-03-10 Nishihara Co., Ltd. Bcl-2 protein expressing agent, apoptosis inhibiting agent and agent for preventing ultraviolet dna damage of epidermal cell
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
DK2736467T3 (en) 2011-07-25 2018-06-25 Tusker Medical Inc PERSONALIZABLE SYSTEM FOR ANTIFICATION OF THE DRUM MAGNET
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US10016304B2 (en) 2015-07-16 2018-07-10 Tusker Medical, Inc. Earplug assembly for iontophoresis system
WO2020219504A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
CA3228635A1 (en) * 2021-08-11 2023-02-16 The Trustees Of The University Of Pennsylvania Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5149628A (en) * 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5328844A (en) 1990-05-09 1994-07-12 University Of Colorado Foundation, Inc. Culture media for mammalian cells
WO1992022640A1 (en) * 1991-06-10 1992-12-23 Research Development Foundation Rb TRANSFERRED CELLS AND METHOD
EP0633934A1 (en) * 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modified cells and method of treatment

Also Published As

Publication number Publication date
US20080102060A1 (en) 2008-05-01
CA2163439A1 (en) 1994-12-08
DK0751709T3 (da) 2002-03-04
US20030069201A1 (en) 2003-04-10
US6514761B1 (en) 2003-02-04
PT751709E (pt) 2001-12-28
EP0751709A1 (en) 1997-01-08
DE69428130D1 (de) 2001-10-04
DE69428130T3 (de) 2006-10-12
JP3704348B2 (ja) 2005-10-12
JP3867033B2 (ja) 2007-01-10
EP0751709B1 (en) 2001-08-29
EP0751709A4 (en) 1997-09-24
CA2163439C (en) 2011-01-04
JPH09502083A (ja) 1997-03-04
US5550019A (en) 1996-08-27
EP0751709B2 (en) 2006-03-29
EP1130087A2 (en) 2001-09-05
JP2003176236A (ja) 2003-06-24
DE69428130T2 (de) 2002-05-02
US7910370B2 (en) 2011-03-22
WO1994027426A1 (en) 1994-12-08
EP1130087A3 (en) 2003-10-29
US7427495B2 (en) 2008-09-23
ATE204704T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
ES2166802T3 (es) Utilizacion de rapamicina para la fabricacion de un medicamento para la prevencion y el tratamiento de las enfermedades vasculares proliferativas, eventualmente en combinacion con el acido micofenolico.
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
DE3882642D1 (de) Substituierte tetraline, chromane und verwandte verbindungen fuer die behandlung von asthma, arthritis und verwandte krankheiten.
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
NO944340D0 (no) Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
BR9808063A (pt) Métodos para tratamento de distúrbios vasculares.
BR9608595A (pt) Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
MX9203208A (es) Composicion farmaceutica y metodo para el tratamiento de trastornos digestivos.
BR9304018A (pt) Processo para o tratamento agroquimico de pastos
ES2058813T3 (es) Un metodo para la fabricacion de un medicamento para el tratamiento de la conmocion.
PT872238E (pt) Utilizacao de olanzapina para o fabrico de um medicamento para neuroproteccao
DK8893D0 (da) Medicament for treatment or prevention of disease
SE8804285L (sv) Anvaendning av dihydroergotamin foer behandling av foerhoejt intrakraniellt tryck
ES1030216Y (es) Cinturon terapeutico para el tratamiento de la impotencia.
BR9405887A (pt) Medicamento para o tratamento de infecções por retrovirus
ITMI920898A0 (it) Apparecchiatura a raggi ultravioletti per la cura mirata di patologie dermatologiche

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751709

Country of ref document: ES